Uncategorized

Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

by Business Wire • 2019/10/09 • 0 Comments

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences announces top-line results for ANX007

← Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and Groundbreaking IOL Data at American Academy of Ophthalmology Annual Meeting

Mynosys Cellular Devices, Inc. Secures $25 Million Investment From Decheng Capital; Names Veteran Ophthalmic Executive Rob Thornhill as CEO →